Gynecologic Oncology
Research activity is centered on epithelial ovarian cancer, with attention to treatment strategies used after initial surgery and chemotherapy. The clinical focus includes disease control in women with ovarian malignancy and the evaluation of ongoing management approaches in the post-treatment setting.
- Ovarian cancer
- Post-treatment maintenance therapy
- Recurrence prevention
The sponsor’s network spans multiple collaborating sites across more than one country, supporting research in gynecologic cancer care and treatment optimization.
Hormone-Responsive Cancer Therapy
Its therapeutic interest includes the use of aromatase inhibitor therapy in a hormone-sensitive malignancy, reflecting a focus on endocrine-based management for ovarian cancer. This area links cancer biology with targeted hormonal treatment in the maintenance setting.
- Endocrine therapy
- Letrozole
- Aromatase inhibition
Research in this domain is directed toward maintaining disease control after standard frontline treatment.
Oncology Outcomes
The sponsor’s trial activity is aligned with clinical outcomes assessment in progression-free survival and other measures of disease stability. This places emphasis on how maintenance treatment influences the course of ovarian cancer over time.
- Progression-free survival
- Disease stabilization
- Clinical effectiveness
These interests support evaluation of long-term disease management in a setting where sustained control is clinically important.
Multicentre Clinical Research
With a broad collaborative structure involving numerous research sites, the sponsor is active in coordinated studies across Switzerland and another participating country. Its research profile includes the organization of multicentre oncology trials in specialist care settings.
- Collaborative research sites
- Cross-border clinical research
- Specialist oncology networks
This activity supports the study of ovarian cancer treatment within a distributed clinical research environment.
